Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a recent publication Raffi et al. suggest that it may be time to drop efavirenz (Sustiva®) from 1st line HIV treatment recommendations [1]. The authors make the claim that efavirenz was inferior to rilpivirin (Edurant®) and dolutegravir (Tivicay®) in a total of 3 recent controlled studies. They review the CNS side effect profile Continue reading Should Efavirenz Remain a Tier 1 ART Drug?
In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”.[1] Regarding the number of drugs in late development, his statement may be correct but many of these drugs are anything but new. Reviewing Continue reading The Antibiotic Pipeline: How “New” is New
An interesting report has just been published showing that Naloxegol is beneficial in OIC [i]. Naloxegol is a µ opioid receptor (MOR) antagonist which – by virtue of pegylation – acts peripherally and not centrally. Hence, the analgesic effects of opioid therapy are unaffected while the very bothersome side effect Continue reading Trial Pains Secondary to Placebo Effect?